Table 3 Clinical characteristics of patients undergoing ATD re-administration.
From: Antithyroid drug-induced leukopenia and G-CSF administration: a long-term cohort study
Case | G-CSF administration | Age (years) | Sex | ATD | ATD course | Comparison with the previous dose of ATD* | Total duration of ATD treatment (days) | Discontinuation period (days) | Re-administration period (days) |
|---|---|---|---|---|---|---|---|---|---|
1 | – | 47 | M | MMI | 2nd | Same | 609 | 321 | 16 |
2 | – | 45 | F | MMI | 3rd | Decreased | 86 | 296 | 21 |
3 | – | 79 | F | MMI/PTU | 2nd | Increased | 77 | 462 | 22 |
4 | – | 51 | F | MMI | 2nd | Increased | 515 | 1240 | 27 |
5 | – | 49 | M | MMI | 2nd | Decreased | 651 | 186 | 30 |
6 | – | 51 | F | MMI | 3rd | Decreased | 171 | 231 | 40 |
7 | – | 45 | M | MMI | 2nd | Same | 472 | 836 | 40 |
8 | – | 53 | M | MMI | 2nd | Increased | 239 | 421 | 43 |
9 | G-CSF | 26 | F | MMI | 2nd | Increased | 375 | 178 | 61 |
10 | G-CSF | 25 | F | MMI | 2nd | Same | 152 | 300 | 62 |
11 | – | 33 | F | MMI/PTU | 2nd | Increased | 537 | 171 | 155 |
12 | – | 45 | M | MMI | 2nd | Decreased | 702 | 200 | 302 |
13 | G-CSF | 50 | F | MMI | 2nd | Same | 920 | 182 | 390 |
14 | – | 35 | F | MMI/PTU | 2nd | Same | 701 | 576 | 646 |
